Class II recall: Baxter Healthcare Corporation: Clindamycin Injection USP in 5% Dextrose, 900 mg/50 mL (18 mg/mL), in GALAXY 50

The FDA has classified as a Class II recall a batch of Clindamycin Injection USP in 5% Dextrose, 900 mg/50 mL (18 mg/mL), packaged in GALAXY 50 mL Single Dose Containers (NDC 43066-995-24) manufactured by Baxter Healthcare Corporation. According to the FDA notice, the recall was initiated due to current Good Manufacturing Practice (CGMP) deviations. The product is Rx only and labeled sterile and nonpyrogenic.

Most relevant for: Patients receiving clindamycin injection for bacterial infections who may have received this specific recalled batch from Baxter Healthcare Corporation

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.